---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-006346"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:43:16.841285+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vir Biotech Q4/FY2023 net loss $116M/$615M; GSK flu pact ended; cash $1.63B

## Summary
- Q4 net loss $116.0M ($0.86 loss per share); FY2023 net loss $615.1M ($4.59 loss per share).
- Q4 revenue $16.8M (down 66% YoY); FY revenue $86.2M (down 95% YoY) on lower sotrovimab sales.
- Cash, cash equivalents and investments $1.63B as of Dec 31, 2023, down $108M in Q4.
- GSK influenza collaboration terminated; Vir retains sole rights to VIR-2482, VIR-2981 and pays low single-digit royalties.
- CMO Phil Pang steps down March 31, 2024; SOLSTICE hepatitis delta trial enrollment ahead of schedule with initial data expected Q2 2024.

## SEC filing metadata
- accession: 0001628280-24-006346
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828024006346/0001628280-24-006346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828024006346/vir-20240221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-006346
- JSON: https://secwatch.observer/filing/0001628280-24-006346.json
- Plain text: https://secwatch.observer/filing/0001628280-24-006346.txt

## Key facts
- Earnings Releases
  Vir Biotechnology, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On February 22, 2024, the Company issued a press release announcing its financial results for the fourth quarter and the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000162828024006346/0001628280-24-006346-index.htm
- Material Agreements
  Vir Biotechnology, Inc. terminated Letter Agreement with Glaxo Wellcome UK Limited (effective 2024-02-21).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Glaxo Wellcome UK Limited
  - Effective: 2024-02-21
  source text: On February 21, 2024, the Parties entered into a letter agreement (the “Letter Agreement”) pursuant to which the Parties mutually agreed to terminate their collaboration on the Influenza Program under the DCA.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000162828024006346/0001628280-24-006346-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.